Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that KRAS p.G12C status confers therapeutic sensitivity to Adagrasib in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized adagrasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and disease progression after at least one prior systemic therapy.
This statement is based on a regulatory approval from the European Medicines Agency:
KRAZATI as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.